Prebase

Prebase may be available in the countries listed below.

Ingredient matches for Prebase

Benazepril

Benazepril hydrochloride (a derivative of Benazepril) is reported as an ingredient of Prebase in the following countries:

• Japan

International Drug Name Search

Nurofen Complex

Nurofen Complex may be available in the countries listed below.

Ingredient matches for Nurofen Complex

Ibuprofen

Ibuprofen is reported as an ingredient of Nurofen Complex in the following countries:

• New Zealand


• Spain

Pseudoephedrine

Pseudoephedrine hydrochloride (a derivative of Pseudoephedrine) is reported as an ingredient of Nurofen Complex in the following countries:

• New Zealand


• Spain

International Drug Name Search

Citalopram TAD

Citalopram TAD may be available in the countries listed below.

Ingredient matches for Citalopram TAD

Citalopram

Citalopram hydrobromide (a derivative of Citalopram) is reported as an ingredient of Citalopram TAD in the following countries:

• Germany

International Drug Name Search

Asamnex

Asamnex may be available in the countries listed below.

Ingredient matches for Asamnex

Tranexamic Acid

Tranexamic Acid is reported as an ingredient of Asamnex in the following countries:

• Indonesia

International Drug Name Search

Cotina

Cotina may be available in the countries listed below.

Ingredient matches for Cotina

Nicotinic Acid

Nicotinic Acid is reported as an ingredient of Cotina in the following countries:

• Chile

International Drug Name Search

Vaniqa

Vaniqa is a brand name of eflornithine topical, approved by the FDA in the following formulation(s):

VANIQA (eflornithine hydrochloride - cream; topical)

• 
  Manufacturer: SKINMEDICA
  
  Approval date: July 27, 2000
  
  Strength(s): 13.9% ^[RLD]

Has a generic version of Vaniqa been approved?

No. There is currently no therapeutically equivalent version of Vaniqa available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vaniqa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Topical composition for inhibiting hair growth
  Patent 5,648,394
  Issued: July 15, 1997
  Inventor(s): Boxall; Brian Alfred & Amery; Geoffrey Wilfred & Ahluwalia; Gurpreet S.
  The present invention embraces a topical composition for inhibiting mammalian hair growth, particularly human beard hair growth (including hirsutism), comprising a water-soluble, hair-growth-inhibiting agent dispersed in an oil-in-water emulsion in the form of a lotion or cream. The invention also embraces a method of inhibiting mammalian hair growth by applying an effective amount of the above composition to the skin. The invention further embraces a topical composition for delivering a pharmacological agent to the skin.
  
  Patent expiration dates:
  
  
  • July 15, 2014
    
    ✓ 
    Patent use: TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR
  
  

See also...

• Vaniqa Consumer Information (Drugs.com)
• Vaniqa Cream Consumer Information (Wolters Kluwer)
• Vaniqa Consumer Information (Cerner Multum)
• Vaniqa Topical Advanced Consumer Information (Micromedex)
• Vaniqa AHFS DI Monographs (ASHP)
• Eflornithine Cream Consumer Information (Wolters Kluwer)
• Eflornithine topical Consumer Information (Cerner Multum)
• Eflornithine Injection Advanced Consumer Information (Micromedex)
• Eflornithine Topical Advanced Consumer Information (Micromedex)
• Eflornithine AHFS DI Monographs (ASHP)